Insmed (NASDAQ:INSM) Sets New 12-Month High – Should You Buy?

Insmed, Inc. (NASDAQ:INSM) hit a new 52-week high on Wednesday . The company traded as high as $162.44 and last traded at $162.32, with a volume of 1627363 shares. The stock had previously closed at $158.28.

Analyst Ratings Changes

INSM has been the topic of a number of recent research reports. HC Wainwright raised their price objective on Insmed from $90.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, June 11th. Citigroup upgraded Insmed to a “buy” rating in a research note on Tuesday, June 10th. Leerink Partners raised their price objective on Insmed from $100.00 to $115.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 10th. Wells Fargo & Company raised their price objective on Insmed from $140.00 to $171.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 3rd. Finally, Stifel Nicolaus raised their price objective on Insmed from $121.00 to $145.00 and gave the stock a “buy” rating in a research note on Thursday, August 14th. Nineteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $149.06.

Insmed Stock Performance

The company has a 50 day moving average price of $134.74 and a 200-day moving average price of $100.23. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45. The company has a market cap of $34.31 billion, a P/E ratio of -28.43 and a beta of 1.03.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business had revenue of $107.42 million during the quarter, compared to the consensus estimate of $104.06 million. During the same quarter in the previous year, the business posted ($1.94) EPS. The company’s revenue for the quarter was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. On average, equities analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Orlov S. Nicole Schaeffer sold 76,520 shares of Insmed stock in a transaction on Friday, September 12th. The stock was sold at an average price of $145.45, for a total value of $11,129,834.00. Following the transaction, the insider owned 36,461 shares in the company, valued at approximately $5,303,252.45. This trade represents a 67.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Michael Alexander Smith sold 24,272 shares of Insmed stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $143.89, for a total value of $3,492,498.08. Following the completion of the transaction, the insider owned 54,902 shares in the company, valued at approximately $7,899,848.78. The trade was a 30.66% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 219,568 shares of company stock worth $28,305,070. 3.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Insmed

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Insmed by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company’s stock valued at $1,393,675,000 after acquiring an additional 49,149 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Insmed by 1.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company’s stock valued at $985,938,000 after acquiring an additional 219,131 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Insmed by 109.2% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company’s stock valued at $262,967,000 after acquiring an additional 1,799,382 shares in the last quarter. Artisan Partners Limited Partnership boosted its holdings in shares of Insmed by 3.0% during the 2nd quarter. Artisan Partners Limited Partnership now owns 3,314,341 shares of the biopharmaceutical company’s stock valued at $333,555,000 after acquiring an additional 97,073 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its holdings in shares of Insmed by 2.5% during the 1st quarter. Alliancebernstein L.P. now owns 2,423,513 shares of the biopharmaceutical company’s stock valued at $184,890,000 after acquiring an additional 59,952 shares in the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.